Affy Founder Fodor to Step Down as CEO in January; King Tapped as Successor

Oct 22, 2008

NEW YORK (GenomeWeb News) – Affymetrix founder, chairman, and CEO Stephen Fodor will relinquish his CEO responsibilities as of Jan. 1, 2009, the company said today.

Fodor will serve as full-time executive chairman, a position in which he will “identify and advance new platform technologies and explore new market opportunities for the company,” Affymetrix said in a statement.

Kevin King, president of Affymetrix, will become CEO and a member of the board of directors on Jan. 1.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Featured White Papers

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Probe Design and In Vitro Validation Quick Start Guide

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu